ESKD, Transplantation, and Dialysis in Lupus Nephritis

Alberto J. Sabucedo, Gabriel Contreras

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Kidney disease resulting from systemic lupus erythematosus accounts for 1.9% of the end-stage kidney disease (ESKD) population in the United States. Systemic lupus erythematosus patients with lupus nephritis (LN) who progress to ESKD in the United States are mostly female (81%) and of African ancestry (49%), with a mean age of 41 years at initiation of renal replacement therapy (RRT). The incidence of ESKD in patients with LN steadily increased between 1982 and 1998 because RRT was offered more readily to LN patients in the United States. However, it appears to have plateaued in the early 2000s, and recently decreased, with approximately 3.26 incident cases per million patient-years during the biennium period of 2009 to 2010. When LN patients approach ESKD, patients and providers must choose among the RRT options available. The trend of the RRT used to support LN ESKD patients is not guided by the lower mortality seen with the use of kidney transplantation compared with dialysis (>85% versus 73% survival during 5 years of follow-up evaluation, respectively). Less than 4% of LN ESKD patients have pre-emptive kidney transplantation. Although the survival of LN ESKD patients who begin with hemodialysis and peritoneal dialysis are similar (77% versus 79% during 3 years of follow-up evaluation, respectively), more than 80% of patients begin with hemodialysis and less than 15% begin with peritoneal dialysis in the United States.

Original languageEnglish (US)
Pages (from-to)500-508
Number of pages9
JournalSeminars in Nephrology
Volume35
Issue number5
DOIs
StatePublished - 2015

Fingerprint

Lupus Nephritis
Kidney Transplantation
Chronic Kidney Failure
Dialysis
Renal Replacement Therapy
Peritoneal Dialysis
Systemic Lupus Erythematosus
Renal Dialysis
Survival
Kidney Diseases

Keywords

  • ESKD
  • Lupus nephritis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Nephrology

Cite this

ESKD, Transplantation, and Dialysis in Lupus Nephritis. / Sabucedo, Alberto J.; Contreras, Gabriel.

In: Seminars in Nephrology, Vol. 35, No. 5, 2015, p. 500-508.

Research output: Contribution to journalArticle

Sabucedo, Alberto J. ; Contreras, Gabriel. / ESKD, Transplantation, and Dialysis in Lupus Nephritis. In: Seminars in Nephrology. 2015 ; Vol. 35, No. 5. pp. 500-508.
@article{1b8bc552797d4b94a4c74343a6c66933,
title = "ESKD, Transplantation, and Dialysis in Lupus Nephritis",
abstract = "Kidney disease resulting from systemic lupus erythematosus accounts for 1.9{\%} of the end-stage kidney disease (ESKD) population in the United States. Systemic lupus erythematosus patients with lupus nephritis (LN) who progress to ESKD in the United States are mostly female (81{\%}) and of African ancestry (49{\%}), with a mean age of 41 years at initiation of renal replacement therapy (RRT). The incidence of ESKD in patients with LN steadily increased between 1982 and 1998 because RRT was offered more readily to LN patients in the United States. However, it appears to have plateaued in the early 2000s, and recently decreased, with approximately 3.26 incident cases per million patient-years during the biennium period of 2009 to 2010. When LN patients approach ESKD, patients and providers must choose among the RRT options available. The trend of the RRT used to support LN ESKD patients is not guided by the lower mortality seen with the use of kidney transplantation compared with dialysis (>85{\%} versus 73{\%} survival during 5 years of follow-up evaluation, respectively). Less than 4{\%} of LN ESKD patients have pre-emptive kidney transplantation. Although the survival of LN ESKD patients who begin with hemodialysis and peritoneal dialysis are similar (77{\%} versus 79{\%} during 3 years of follow-up evaluation, respectively), more than 80{\%} of patients begin with hemodialysis and less than 15{\%} begin with peritoneal dialysis in the United States.",
keywords = "ESKD, Lupus nephritis, Systemic lupus erythematosus",
author = "Sabucedo, {Alberto J.} and Gabriel Contreras",
year = "2015",
doi = "10.1016/j.semnephrol.2015.08.011",
language = "English (US)",
volume = "35",
pages = "500--508",
journal = "Seminars in Nephrology",
issn = "0270-9295",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - ESKD, Transplantation, and Dialysis in Lupus Nephritis

AU - Sabucedo, Alberto J.

AU - Contreras, Gabriel

PY - 2015

Y1 - 2015

N2 - Kidney disease resulting from systemic lupus erythematosus accounts for 1.9% of the end-stage kidney disease (ESKD) population in the United States. Systemic lupus erythematosus patients with lupus nephritis (LN) who progress to ESKD in the United States are mostly female (81%) and of African ancestry (49%), with a mean age of 41 years at initiation of renal replacement therapy (RRT). The incidence of ESKD in patients with LN steadily increased between 1982 and 1998 because RRT was offered more readily to LN patients in the United States. However, it appears to have plateaued in the early 2000s, and recently decreased, with approximately 3.26 incident cases per million patient-years during the biennium period of 2009 to 2010. When LN patients approach ESKD, patients and providers must choose among the RRT options available. The trend of the RRT used to support LN ESKD patients is not guided by the lower mortality seen with the use of kidney transplantation compared with dialysis (>85% versus 73% survival during 5 years of follow-up evaluation, respectively). Less than 4% of LN ESKD patients have pre-emptive kidney transplantation. Although the survival of LN ESKD patients who begin with hemodialysis and peritoneal dialysis are similar (77% versus 79% during 3 years of follow-up evaluation, respectively), more than 80% of patients begin with hemodialysis and less than 15% begin with peritoneal dialysis in the United States.

AB - Kidney disease resulting from systemic lupus erythematosus accounts for 1.9% of the end-stage kidney disease (ESKD) population in the United States. Systemic lupus erythematosus patients with lupus nephritis (LN) who progress to ESKD in the United States are mostly female (81%) and of African ancestry (49%), with a mean age of 41 years at initiation of renal replacement therapy (RRT). The incidence of ESKD in patients with LN steadily increased between 1982 and 1998 because RRT was offered more readily to LN patients in the United States. However, it appears to have plateaued in the early 2000s, and recently decreased, with approximately 3.26 incident cases per million patient-years during the biennium period of 2009 to 2010. When LN patients approach ESKD, patients and providers must choose among the RRT options available. The trend of the RRT used to support LN ESKD patients is not guided by the lower mortality seen with the use of kidney transplantation compared with dialysis (>85% versus 73% survival during 5 years of follow-up evaluation, respectively). Less than 4% of LN ESKD patients have pre-emptive kidney transplantation. Although the survival of LN ESKD patients who begin with hemodialysis and peritoneal dialysis are similar (77% versus 79% during 3 years of follow-up evaluation, respectively), more than 80% of patients begin with hemodialysis and less than 15% begin with peritoneal dialysis in the United States.

KW - ESKD

KW - Lupus nephritis

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84961589526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961589526&partnerID=8YFLogxK

U2 - 10.1016/j.semnephrol.2015.08.011

DO - 10.1016/j.semnephrol.2015.08.011

M3 - Article

VL - 35

SP - 500

EP - 508

JO - Seminars in Nephrology

JF - Seminars in Nephrology

SN - 0270-9295

IS - 5

ER -